Trial Profile
Phase Ib/II Study of Concurrent Durvalumab And Radiation Therapy (DUART) Followed by Adjuvant Durvalumab in Patients With Urothelial Cancer (T2-4 N0-2 M0) of the Bladder: Big Ten Cancer Research Consortium BTCRC-GU15-023
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Bladder cancer; Carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms DUART
- 13 Feb 2021 Results presented at the 2021 Genitourinary Cancers Symposium
- 05 Jan 2021 Planned End Date changed from 1 Nov 2021 to 1 Mar 2022.
- 05 Jan 2021 Planned primary completion date changed from 1 Nov 2020 to 1 Mar 2021.